Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced the successful completion of its human clinical study GLP-1-H25-5. The study compared oral capsules of DehydraTECH-liraglutide to the injected Saxenda®-branded liraglutide. Partial results from the study are now available and indicate a pronounced reduction in adverse events associated with the oral DehydraTECH-liraglutide. Lexaria has demonstrated reductions in adverse events across all three major GLP-1 drugs: liraglutide, semaglutide, and tirzepatide, in distinct clinical human studies. Currently, Lexaria is seeking a pharmaceutical partner to support an FDA-registered oral alternative to the existing injectable GLP-1 brands.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。